

Disease Modifying Therapies for the Treatment for the Treatment of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Stakeholder List

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input as well as those that have provided public comments during the review. All of the organizations and individuals below have been invited to provide input, however, it should not be assumed that they have responded to ICER's outreach or agreed to participate in this review.

- Amyloidosis Foundation
- Amyloidosis Research Consortium
- Amyloidosis Support Groups
- Alnylam Pharmaceuticals
- AstraZeneca
- Bridgebio Pharma
- Ionis Pharmaceutical
- IPD Analytics
- Mackenzie's Mission
- Mended Hearts and American Health Association
- Pfizer

We spoke with several additional experts in the preparation of this report. Of them, the following individuals have agreed to be identified as having spoken with ICER:

- **Marianna Fontana, MD, PhD**, Director, Cardiac Magnetic Resonance Imaging Unit, Royal Free Hospital; Professor of Cardiology and Honorary Consultant Cardiologist, National Amyloidosis Centre, Division of Medicine, University College London
- **Michelle Kittleson, MD, PhD**, Director of Education in Heart Failure and Transplantation, Director of Heart Failure Research, and Professor of Medicine at the Smidt Heart Institute, Cedars-Sinai.

Hypertrophic Cardiomyopathy Center, Oregon Health &
Science University

- **Mathew Maurer, MD,** Professor of Cardiology and Director of Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), Columbia University Irving Medical Center
- **Frederick Ruberg, MD,** Chief of Cardiovascular Medicine, Boston Medical Center; Thomas J. Ryan Professor of Cardiovascular Medicine and Section Chief of Cardiovascular Medicine, Boston University School of Medicine

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).